[153Sm]EDTMP: a potential therapy for bone cancer pain.
Reactor-produced samarium-153 (153Sm) is both a beta and gamma emitter with a physical half-life of 46.3 hours. When complexed with EDTMP, more than 50% of the administered dose localizes in bone. A therapeutic trial on patients with painful bone metastases performed at the University of Missouri produced relief in 65.4% of the patients who were evaluable. Myelotoxicity was mild and transient. For [153Sm]EDTMP to attain clinical utility, studies demonstrating its efficacy as an analgesic must be performed to exclude a "ligand analgesic effect".
Holmes
R A
RA
Medicine Department, King/Drew Medical Center, Los Angeles, CA 90059.
D000818:Animals; D001859:Bone Neoplasms / Q000503:physiopathology / Q000556:secondary*; D004285:Dogs; D006801:Humans; D009369:Neoplasms / Q000209:etiology / Q000532:radiotherapy*; D009942:Organometallic Compounds / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000627:therapeutic use*
D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; C061972:samarium Sm-153 lexidronam